Global Arteriotomy Closure Devices Market Forecast for 2020 to 2025

October 21, 2020

Global Arteriotomy Closure Devices: The major factors attributing to the growth of the arteriotomy closure devices market are increasing incidences of vascular disorders and rising geriatric population.

The global increase in the incidence of vascular diseases is due to a sedentary lifestyle, unhealthy diet, and smoking. Cardiovascular diseases include coronary heart disease, stroke, high blood pressure, artery diseases, etc. According to the American Heart Association, in 2017, around 43% of the deaths occurs due to coronary heart disease in the United States. Manual compression has been considered the traditional technique to achieve closure of the arterial access site. Patient comfort and satisfaction are the important factors that result in wide adoption of arteriotomy closure devices.

Key Market Trends

Femoral Arterial Access is Highly Preferred in the Application Segment

The vast majority of procedures are performed with Femoral arterial access. However, increased interest has been observed for the radial approach due to the significant reduction in bleeding complications.

Vascular complications increase depending on the severity of the procedure. In order to reduce these complications, ACDs have been developed as an alternative to manual compression. The use of Arteriotomy Closure Devices is recommended to patients undergoing acute myocardial infarction, neurovascular interventions and endovascular procedures for peripheral vascular diseases. With the increasing incidence of vascular disorders as well as the development of innovative products, the growth of the market is expected to be augmented.

North America Dominates the Market and Expected to do same in the Forecast Period

North America will witness the highest growth throughout the forecast period. This is due to the increasing prevalence of lifestyle disease, rising aging population and growing demand for newly introduced devices and innovative technologies. According to American College of Cardiology’s National Cardiovascular Data Registry (ACC-NCDR, 2018), less than 2% of invasive cardiovascular procedures are performed from the radial site, which indicates that the common femoral artery remains the most common arterial access site in the United States. In the North America region, the United States holds the largest market share.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidences of Vascular Disorders

4.2.2 Rising Geriatric Population

4.3 Market Restraints

4.3.1 High Cost of the Device

4.3.2 Risk Associated With the Procedure

4.4 Porter’s Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Products

5.1.1 Active Closure Devices

5.1.2 Passive Closure Devices

5.2 By Application

5.2.1 Femoral Arterial Access Procedures

5.2.2 Radial Arterial Access Procedures

5.3 By End User

5.3.1 Hospitals

5.3.2 Ambulatory Care Centers

5.3.3 Others

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle-East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle-East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 Cardinal Health

6.1.3 Cardiva Medical

6.1.4 Marine Polymer Technologies Inc

6.1.5 Medtronic PLC

6.1.6 Merit Medical

6.1.7 Teleflex Incorporated

6.1.8 Terumo Corporation

6.1.9 Vasorum Ltd

6.1.10 Vivasure Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

More here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version